Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sagopilone in Metastatic Melanoma
NCT00598507Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- May 2007
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sagopilone in melanoma, sponsored by Moffitt Cancer Center. Primary endpoint: Response Rate up to 5 years. Started May 2007; status: completed.
02
Drugs
sagopilone
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00598507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00598507.